Jupiros CV 10 Capsule is a combination medication containing Rosuvastatin 10 mg and Clopidogrel 75 mg, indicated for the management of cardiovascular conditions requiring both lipid-lowering and antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby mitigating the risk of atherosclerosis and subsequent cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by irreversibly blocking the P2Y12 component of ADP receptors on platelet surfaces, reducing the risk of thrombotic events such as myocardial infarction and stroke. The combined action of these agents provides a synergistic approach to cardiovascular risk reduction in patients with established coronary artery disease, peripheral arterial disease, or those at high risk of thrombotic complications. Jupiros CV 10 Capsule should be administered under medical supervision, with dosage adjustments based on individual patient response and tolerability. Monitoring of liver function, lipid profile, and hematological parameters is recommended during therapy. Contraindications include active bleeding, severe hepatic impairment, and hypersensitivity to either component. Adverse effects may include myopathy, gastrointestinal disturbances, and bleeding tendencies. Patient adherence to prescribed therapy and lifestyle modifications is essential for optimal therapeutic outcomes.